Chemopreventive and Therapeutic Potential of Biomolecules in Gastrointestional Cancer

A special issue of Biomolecules (ISSN 2218-273X).

Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 254

Special Issue Editor


E-Mail Website
Guest Editor
Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402204, Taiwan
Interests: anticancer natural products; cancer stem cells; drug resistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Gastrointestinal cancers, including colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, liver cancer, and pancreatic cancer, are among the most commonly diagnosed and prevalent cancers globally. Despite the implementation of advances in therapeutic treatment, such as targeted therapies and immunotherapies, gastrointestinal cancers still account for more cancer-related deaths than other types of malignancies. In light of this, identification of new approaches to prevent and treat gastrointestinal cancers is urgent. It is noteworthy that biomolecules from natural sources, such as microorganisms, animals and plants, are invaluable resources for novel cancer chemopreventive and therapeutic agents. Accordingly, this Special Issue of Biomolecules is dedicated to original research and review articles that delineate the chemopreventive and therapeutic potential of biomolecules with clearly defined molecular mechanisms in gastrointestinal cancer.

Prof. Chia-che Chang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Gastrointestinal cancers
  • Chemoprevention
  • Cancer therapy
  • Natural products
  • Inflammation
  • Oxidative stress
  • Apoptosis
  • Autophagy
  • Necroptosis
  • Pyroptosis
  • Ferroptosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop